June 28, 2017 10:45 AM ET


Company Overview of Alvogen, Inc.

Company Overview

Alvogen, Inc. manufactures generic and brand medicines, biosimilars, and over the counter (OTC) medicines. The company focuses on niche generics, pathces, controlled releases, and narcotics in various forms, including solid oral dosage forms, soft gelatin capsules, modified release tablets, transdermals, creams, ointments, and injectables. Its portfolio includes a range of molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology, and gastroenterology. The company also sells and markets a portfolio of OTC medicines and medical devices. In addition, it promotes and distributes a range of biosimilar products in various therapeutic areas; and offers...

10 Bloomfield Avenue

Pine Brook, NJ 07058

United States

Founded in 2008





Key Executives for Alvogen, Inc.

Executive Chairman and Chief Executive Officer
Interim Chief Financial Officer
Executive Vice President of Global Operations
Member of Executive Board and Chief Executive Officer of Alvogen America
Age: 46
President of Alvogen America
Compensation as of Fiscal Year 2016.

Alvogen, Inc. Key Developments

Alvogen, Inc. Wins $32,885,990 Federal Contract

Alvogen Inc. won a federal contract modification valued at up to $32,885,990 from the U.S. Department of Veterans Affairs for drugs, pharmaceuticals and hematology related products.

Alvogen to Market Kerecis Regenerative Fish Skin in Korea, Taiwan and Thailand

Alvogen will market the Kerecis fish-skin-based diabetic wound treatment products in Asia starting in Korea, Taiwan and Thailand. The Omega3-rich regenerative tissue products are used to treat chronic wounds, including diabetic wounds. The Kerecis products will support Alvogen's hospital portfolio.

Alvogen Launches First Generic Equivalent of Copaxone™ in Europe

Alvogen announced the launch of Remurel™ the first generic equivalent of Copaxone™ in Central and Eastern Europe. The product will be marketed as a once daily subcutaneous 20 mg prefilled syringe under the brand name Remurel™ and will be launched throughout all Central and Eastern European countries from September 2016 onwards. The product will be launched with a proprietary auto-injector device having multiple features to help support MS patients in their treatment with Remurel™. Teva‘s Copaxone™ delivered sales of over EUR 510 million in Europe in 2015.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

November 28, 2016
OOO Dolfin
November 28, 2016
OOO Dolphin

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Alvogen, Inc., please visit www.alvogen.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.